|Alexandra Okmian||Senior Business Development and Investor Relations Manager|
|Dror Ben-Asher||Chief Executive Officer|
|Guy Goldberg||Chief Business Officer|
|Gilead Raday||Chief Operating Officer|
|Rob Jackson||Senior Vice President, Sales and Marketing|
|Micha Ben-Chorin||Chief Financial Officer|
|Rick Scruggs||Chief Commercial Officer|
|Adi Frish||Chief Corporate and Business Development Officer|
|Bob Gilkin||Senior Vice President, Market Access and Trade Relations|
|Boobalan Pachaiyappan||H.C. Wainwright|
|Matthew Kaplan||Ladenburg Thalmann|
|Scott Henry||ROTH Capital Partners|
Good day, and welcome to the RedHill Biopharma Second Quarter 2021 Financial Results Conference Call. [Operator Instructions] At this time, I would like to introduce to the conference call RedHill's CEO, Dror Ben-Asher; Micha Ben-Chorin, Chief Financial Officer; Rick Scruggs, Chief Commercial Officer; Gilead Raday, Chief Operating Officer; Guy Goldberg, Chief Business Officer; Adi Frish, Chief Corporate and Business Development Officer; Rob Jackson, Senior Vice President, Sales and Marketing; and Bob Gilkin, Senior VP, Market Access and Trade Relations.
Before we begin, we will read from the RedHill's safe harbor statement. Please go ahead.
Thank you, Andrea.